Enterprise Value
-9.057M
Cash
34.22M
Avg Qtr Burn
-4.135M
Short % of Float
1.40%
Insider Ownership
0.46%
Institutional Own.
7.41%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rigosertib Details Cutaneous squamous cell carcinoma, Solid tumor/s, Cancer | Phase 2 Data readout | |
Narazaciclib w/ letrozole Details Solid tumor/s, Cancer, Endometrial cancer | Phase 1/2 Data readout | |
Rigosertib (RAS inhibitor) + Nivolumab + pembrolizumab Details Non-small cell lung carcinoma, Cancer, Cutaneous squamous cell carcinoma | Phase 1/2 Data readout | |
Narazaciclib (ON 123300) (CDK4/6 & ARK5 inhibitor) Details Solid tumor/s, Cancer, Breast cancer, ER+/HER2- breast cancer, Metastatic breast cancer | Phase 1 Update | |
Rigosertib Details Myelodysplastic syndrome | Failed Discontinued |